The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1654
July 11, 2022
View Complete Issue         Table of Contents 2019 
Daridorexant (Quviviq) for Insomnia
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Daridorexant (Quviviq) for Insomnia
July 11, 2022 (Issue: 1654)
The FDA has approved daridorexant (Quviviq – Idorsia), an orexin receptor antagonist, for treatment of sleep-onset and/or sleep-maintenance insomnia in adults. Daridorexant is the third orexin receptor antagonist to be approved for this...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Daridorexant (Quviviq) for Insomnia
Article code: 1654b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.